UA64800C2 - Antiseptic for eyes - Google Patents
Antiseptic for eyes Download PDFInfo
- Publication number
- UA64800C2 UA64800C2 UA2001010041A UA200110041A UA64800C2 UA 64800 C2 UA64800 C2 UA 64800C2 UA 2001010041 A UA2001010041 A UA 2001010041A UA 200110041 A UA200110041 A UA 200110041A UA 64800 C2 UA64800 C2 UA 64800C2
- Authority
- UA
- Ukraine
- Prior art keywords
- eyes
- antiseptic
- same
- group
- animals
- Prior art date
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
заявлених за формою винаходу. Заявлений очний антисептик нешкідливий для організму і є високоефективним засобом для лікування гнійно-запальних уражень очей.claimed according to the form of the invention. The declared eye antiseptic is harmless to the body and is a highly effective means for the treatment of purulent-inflammatory lesions of the eyes.
Таблиця 1Table 1
Склади очного антисептику за експериментальними групамиFormulations of eye antiseptic according to experimental groups
КомпонентиComponents
Мірамістин 0,005Miramistin 0.005
Розріджувач до 100 до 100 до 100 до 100Thinner to 100 to 100 to 100 to 100
Склад розріджувачаThe composition of the thinner
ІРХН 996 2 щ- | (9950 2 7 щ-| 100 | 00IRKHN 996 2 sh- | (9950 2 7 sh-| 100 | 00
Гідроксиетилцелюлоза | 04 | - | - |! -Hydroxyethyl cellulose | 04 | - | - |! -
Метилцелюлоза ниж шишки Пи ПОMethylcellulose is lower than Pi PO cones
Таблиця 2.Table 2.
Результати лікування гнійно-запальних уражень роговиці очей у кролів ЗС і препаратом порівнянняThe results of the treatment of purulent-inflammatory lesions of the cornea in rabbits with ZS and a comparison drug
Ознаки терапевтичного | Номер групи ефе тарин | 2 1. 3 Її 4 1 5 | 6 ЇЇ 7 | в ЇЇ 10 | 12114 | 16 | 18 | »Signs of therapeutic | Number of the group Efe tarin | 2 1. 3 Her 4 1 5 | 6 HER 7 | in HER 10 | 12114 | 16 | 18 | »
Відсутність гнійного Іа 48(10) 92(10) 100010) | т.саме | т.саме | т.саме | т.саме | т.саме | т.саме | тсаме | т.саме | т.саме | т.саме відокремлюваним очей 16 36(8) 84(8) 99(8) 100(8) | т.саме | т.саме | т.саме | т.саме | т.саме | т.саме ) т.саме | т.саме ) т.саме 18 8(8) 15(8) 56(8) 86(8) 96(8) | 100(8) | т.саме | т.саме | т.саме | т.саме | т.саме | т.саме | т.саме 2 1909) 14(9) 58(9) 90(9) 10009) | т.саме | т.саме | т.саме | т.саме | т.саме | т.саме | т.саме | т.саме 3 (6) (6) (6) дб) Ф(6у 1406) | 5205) | 68(6) | 6806) | 8706) | 8706) | 8806) | 109(6)Absence of purulent Ia 48(10) 92(10) 100010) | i.e. | i.e. | i.e. | i.e. | i.e. | i.e. | tsame | i.e. | i.e. | i.e. separable eyes 16 36(8) 84(8) 99(8) 100(8) | i.e. | i.e. | i.e. | i.e. | i.e. | t.same ) t.same | t.same ) t.same 18 8(8) 15(8) 56(8) 86(8) 96(8) | 100(8) | i.e. | i.e. | i.e. | i.e. | i.e. | i.e. | i.e. 2 1909) 14(9) 58(9) 90(9) 10009) | i.e. | i.e. | i.e. | i.e. | i.e. | i.e. | i.e. | i.e. 3 (6) (6) (6) db) F(6y 1406) | 5205) | 68(6) | 6806) | 8706) | 8706) | 8806) | 109(6)
Відсутність 5.айгей5 іа (10) 92410) 100010) | т.саме | т.саме | т.саме | т.саме | т.саме | т.саме | т.саме | т.саме | т.саме | т.саме відокремлюючого очей 16 Ф(8) 52(8) 86080 | 10008) | т.саме ) т.саме | т.саме | т.саме | т.саме | т.саме | т.саме | т.саме | т.семе ів 0(8) 42(8) 648) 92(8) 100(8) | т.саме | т.саме | т.саме ) т.саме | тсаме | т.саме | т.саме | т.саме 2 Ф(9) 46(9) сво 90(9) 10009) | т.саме | т.саме | т.саме | т.саме | т.саме | т.саме | т.саме | т.самеAbsence 5.aygey5 ia (10) 92410) 100010) | i.e. | i.e. | i.e. | i.e. | i.e. | i.e. | i.e. | i.e. | i.e. | that is, of the separating eye 16 F(8) 52(8) 86080 | 10008) | t.same ) t.same | i.e. | i.e. | i.e. | i.e. | i.e. | i.e. | t.seme iv 0(8) 42(8) 648) 92(8) 100(8) | i.e. | i.e. | t.same ) t.same | tsame | i.e. | i.e. | i.e. 2 F(9) 46(9) svo 90(9) 10009) | i.e. | i.e. | i.e. | i.e. | i.e. | i.e. | i.e. | i.e
Е об) о(6) (6) об о(63 | 1466) | 52063 | 6806) | 6806) | 8706) | 8706) | 8706) | 10006)E ob) o(6) (6) o o(63 | 1466) | 52063 | 6806) | 6806) | 8706) | 8706) | 8706) | 10006)
Розсмоктування гвійного іа 9019) 4819) 74410) | 100010) | т.саме | т.саме | т.саме | т.саме | т.саме | т.саме | т.саме | тсаме | т.саме інфільтрату 16 (8) 38(8) б66(8) 92(8) 100(8) | т.саме | т.саме | т.саме | т.саме | т.саме | т.саме | т.саме | т.саме ів о(8) 10(8) 38(8) 428) 5808) ! 66(8) 86(8) 94(8) | 100(8) | т.саме | т.саме | т.саме | т.саме 2 09) о(9у 1209) 46(9) 5809) | 6809) | 9009) | 100093 | т.саме | т.саме | т.саме | тсаме | т.саме 3 (6) Ф(6 о(б) що (б) дб) 18(6) | 18065 | 3605) | 36065 | 3605) | 66(6) | 68(6)Resorption of the spinal cord 9019) 4819) 74410) | 100010) | i.e. | i.e. | i.e. | i.e. | i.e. | i.e. | i.e. | tsame | i.e. infiltrate 16 (8) 38(8) b66(8) 92(8) 100(8) | i.e. | i.e. | i.e. | i.e. | i.e. | i.e. | i.e. | i.e. iv o(8) 10(8) 38(8) 428) 5808) ! 66(8) 86(8) 94(8) | 100(8) | i.e. | i.e. | i.e. | i.e. 2 09) o(9u 1209) 46(9) 5809) | 6809) | 9009) | 100093 | i.e. | i.e. | i.e. | tsame | i.e. 3 (6) F(6 o(b) what (b) db) 18(6) | 18065 | 3605) | 36065 | 3605) | 66(6) | 68(6)
Епітелізація 1а 22(10) 3210) 32410) | 54(10) | 80010) | 82010) | 86(10) | 1000103 | т.саме | т.саме | т.саме | т.саме ; т.саме 16 1608) 26(8) 3008) | 44083 | 5608) | 6408) | 76(8У | 8803) | 100(8) | т.саме | т.саме | т.саме | т.самеEpithelialization 1a 22(10) 3210) 32410) | 54(10) | 80010) | 82010) | 86(10) | 1000103 | i.e. | i.e. | i.e. | i.e. the same i.e. 16 1608) 26(8) 3008) | 44083 | 5608) | 6408) | 76(8U | 8803) | 100(8) | i.e. | i.e. | i.e. | i.e
Ів В) 483 (8) 10083 | 1208у | 22083 | 2208) | 3483 | з8(8) | 68(83 | 9208 | 10008) | т.саме 2 (9) (9) 0(9) 12093 | 12093 | 2509) | 2509) | 360) | з6(9) | 79093 | 10009) | т.саме | т.саме 3 (6 (6 006) | о (6 (6 (6 06) | 18066) | 1806) | зе) | 3605) | 526Iv V) 483 (8) 10083 | 1208u | 22083 | 2208) | 3483 | z8(8) | 68(83 | 9208 | 10008) | i.e. 2 (9) (9) 0(9) 12093 | 12093 | 2509) | 2509) | 360) | z6(9) | 79093 | 10009) | i.e. | i.e. 3 (6 (6 006) | o (6 (6 (6 06) | 18066) | 1806) | ze) | 3605) | 526
Примітка: "7 -1а група тварин, яка отримавала склад іа -16 група тварин, яка отримавала склад 16 -Ів група тварин, яка отримавала склад 18 -2 група тварин, яка отримавала софрадекс -3 контрольна група тварин, яка отримавала ІРХН жж - у дужках кількість очей, які були оглянутіNote: "7 - 1a group of animals that received composition ia - 16 group of animals that received composition 16 - IV group of animals that received composition 18 - 2 group of animals that received sofradex - 3 control group of animals that received IRCHN zhzh - in parentheses is the number of eyes that were examined
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2000110541A RU2164135C1 (en) | 2000-04-27 | 2000-04-27 | Ophthalmic antiseptic agent |
Publications (1)
Publication Number | Publication Date |
---|---|
UA64800C2 true UA64800C2 (en) | 2004-03-15 |
Family
ID=20233909
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UA2001010041A UA64800C2 (en) | 2000-04-27 | 2001-03-20 | Antiseptic for eyes |
Country Status (3)
Country | Link |
---|---|
EA (1) | EA003408B1 (en) |
RU (1) | RU2164135C1 (en) |
UA (1) | UA64800C2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011101113A1 (en) | 2010-02-19 | 2011-08-25 | Megainpharm Gmbh | Pharmaceutical comprising myramistin |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102008039254A1 (en) | 2008-08-20 | 2010-02-25 | Megainpharm Gmbh | Medicament, useful e.g. for treating infectious- and purulent inflammatory diseases of e.g. eyes, comprises benzyl-dimethyl-(3-(myristoylamino)-propyl)-ammonium chloride, dimethyl-(3-(myristoylamino)-propyl)-amine oxide and solvent |
WO2014175757A1 (en) | 2013-04-22 | 2014-10-30 | Общество с ограниченной ответственностью "Нанобиотех" | Antiseptic veterinary formulation and methods for use thereof |
RU2755298C1 (en) * | 2020-11-09 | 2021-09-15 | Юлия Александровна Корнева | Contact lens care solution |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU1832496A1 (en) * | 1978-08-02 | 1996-04-27 | Н.М. Овчинников | Antiseptic agent "miramistin" for venereal disease prophylaxis |
RU2139095C1 (en) * | 1998-04-23 | 1999-10-10 | Научно-производственное предприятие ООО "ЛИНКО" | Enzymatic composition for cleaning contact lenses |
RU2139094C1 (en) * | 1998-04-23 | 1999-10-10 | Научно-производственное предприятие ООО "ЛИНКО" | Composition for treating contact lenses |
-
2000
- 2000-04-27 RU RU2000110541A patent/RU2164135C1/en active
-
2001
- 2001-02-28 EA EA200100197A patent/EA003408B1/en not_active IP Right Cessation
- 2001-03-20 UA UA2001010041A patent/UA64800C2/en unknown
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011101113A1 (en) | 2010-02-19 | 2011-08-25 | Megainpharm Gmbh | Pharmaceutical comprising myramistin |
WO2011100994A1 (en) * | 2010-02-19 | 2011-08-25 | Megainpharm Gmbh | Pharmaceutical comprising myramistin |
EA022283B1 (en) * | 2010-02-19 | 2015-12-30 | Мегаинфарм Гмбх | Pharmaceutical comprising benzyldimethyl[3-(myristoylamino)propyl]ammonium chloride |
MD4411C1 (en) * | 2010-02-19 | 2016-11-30 | Megainpharm Gmbh | Pharmaceutical including benzyldimethyl(3-[myristoylamino]propyl)-ammonium chloride and its use for the treatment and prevention of infectious and pyoinflammatory diseases of different etiology and localization |
Also Published As
Publication number | Publication date |
---|---|
EA200100197A1 (en) | 2001-12-24 |
RU2164135C1 (en) | 2001-03-20 |
EA003408B1 (en) | 2003-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2595132C (en) | Agents for controlling biological fluids and methods of use thereof | |
US8535709B2 (en) | Agents for controlling biological fluids and methods of use thereof | |
JP2611159B2 (en) | Hyaluronic acid pharmacologically active fraction, method for producing the same and pharmaceutical composition | |
US20070059350A1 (en) | Agents for controlling biological fluids and methods of use thereof | |
CA2341410C (en) | Hydrogel compositions for the controlled release administration of growth factors | |
MXPA04000764A (en) | Synergistic antimicrobial ophthalmic and dermatologic preparations containing chlorite and hydrogen peroxide. | |
CN103182070B (en) | External composition, and preparation and application thereof | |
Ballard et al. | Developments in wound care for difficult to manage wounds | |
KR20210075051A (en) | Composition for for treating wound or scar comprising hydrogel patches | |
CN112272578A (en) | Sodium chlorite compositions with enhanced antimicrobial efficacy and reduced toxicity | |
US7807656B2 (en) | Pharmaceutical applications of hyaluronic acid preparations | |
Milburn et al. | Treatment of scleroderma skin ulcers with a hydrocolloid membrane | |
UA64800C2 (en) | Antiseptic for eyes | |
US20180200340A1 (en) | Wound Treatment | |
Gupta et al. | Calcium alginate in the management of acute surgical wounds and abscesses | |
JP5796728B1 (en) | A biofilm for the purpose of promoting wound healing and covering (coaching) and protecting living organs. | |
US11576926B2 (en) | Composition for use in the prevention and/or treatment of epistaxis | |
EP2590666B1 (en) | Topical application of erythropoietin for use in the treatment of injuries of the cornea | |
MXPA01003507A (en) | Synergistic antimicrobial, dermatological and ophthalmic preparations containing chlorite and hydrogen peroxide. | |
Dziewulski et al. | Acute management of facial burns | |
Ghosh et al. | Preclinical and clinical study of polysaccharide-based hydrogels | |
RU2319487C1 (en) | Composition for antibacterial dressing material and method for treatment of suppurative wounds | |
Santhan | A Comparative Study between Efficacy Of Topical Sucralfate And 5% Povidone Iodine In Chronic Lower Limb Ulcers | |
RU2192266C2 (en) | Method for preparing skin cover defect to autodermoplasty operation | |
MILLER et al. | The Use of the Antibacterial Drugs and Streptokinase: Administered Intramuscularly in Enucleation of the Eye. |